Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and ...

Economist David C. Datelle says the pharmaceutical industry's prices have less to do with innovation than with corporate ...

NINGBO, ZHEJIANG PROVINCE, CHINA, January 21, 2026 /EINPresswire.com/ -- In recent years, the global life science ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this year, calling on the industry to reinvent R&D, design enduring ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

Merck's CEO Rob Davis emphasizes DEI as a strategic imperative, aligning it with scientific rigor and innovation, showcasing ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

The opening session sets the context and intent for the Inaugural Summit: USA-Saudi Biotech Alliance, outlining the strategic ...

China’s biotech sector is surging. For the first time, it now leads the world in clinical trials and new drug licensing. The U.S., once the undisputed leader in pharmaceutical innovation, risks losing ...

It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...